Publications - Neil E . Kay, M.D.

Back to Research Profile

1. Van Dyke DL, Shanafelt TD, Call TG, Zent CS, Smoley SA, Rabe KG, Schwager SM, Sonbert JC, Slager SL, Kay NE. A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia. Br J Haematol 2009 Nov 06. [Epub ahead of print]
   View PubMed
2. Ding W, Nowakowski GS, Knox TR, Boysen JC, Maas ML, Schwager SM, Wu W, Wellik LE, Dietz AB, Ghosh AK, Secreto CR, Medina KL, Shanafelt TD, Zent CS, Call TG, Kay NE. Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br J Haematol 2009 Nov; 147(4):471-83. Epub 2009 Sep 08.
   View PubMed
3. Lacy MQ, Jacobus S, Blood EA, Kay NE, Rajkumar SV, Greipp PR. Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group. Leuk Res 2009 Nov; 33(11):1485-9. Epub 2009 Feb 24.
   View PubMed
4. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Jager U, Gandhi V, Kay NE, Plunkett W, Burger JA. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009 Sep 17. [Epub ahead of print]
   View PubMed
5. Shanafelt TD, Byrd JC, LaPlant B, Zent CS, Call T, Secreto C, Grever MR, Lin TS, Kay NE. Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia. Br J Haematol 2009 Sep; 146(6):660-4.
   View PubMed
6. Shanafelt TD, Byrd JC, LaPLant B, Zent CS, Call T, Secreto C, Grever MR, Lin TS, Kay NE. Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia. Br J Haematol 2009 Sep; 146(6):660-4. Epub 2009 Jul 10.
   View PubMed
7. Shanafelt TD, Kay NE, Rabe KG, Call TG, Zent CS, Maddocks K, Jenkins G, Jelinek DF, Morice WG, Boysen J, Schwager S, Bowen D, Slager SL, Hanson CA. Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol 2009 Aug 20; 27(24):3959-63. Epub 2009 Jul 20.
   View PubMed
8. Shanafelt TD, Call TG, Zent CS, LaPlant B, Bowen DA, Roos M, Secreto CR, Ghosh AK, Kabat BF, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 2009 Aug 10; 27(23):3808-14. Epub 2009 May 26.
   View PubMed
9. Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, O'Brien S, Ferrajoli A, Lerner SA, Lynn A, Kay NE, Keating MJ. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood 2009 Jul 30; 114(5):957-64. Epub 2009 May 04.
   View PubMed
10. Nowakowski GS, Shanafelt TD, Schwager S, Kay NE. Reply to R.S. Go. J Clin Oncol 2009 Jul 06. [Epub ahead of print]
    View PubMed
11. Cerhan JR, Novak AJ, Fredericksen ZS, Wang AH, Liebow M, Call TG, Dogan A, Witzig TE, Ansell SM, Habermann TM, Kay NE, Slager SL. Risk of non-Hodgkin lymphoma in association with germline variation in complement genes. Br J Haematol 2009 Jun; 145(5):614-23. Epub 2009 Mar 30.
    View PubMed
12. Ghosh AK, Shanafelt TD, Cimmino A, Taccioli C, Volinia S, Liu CG, Calin GA, Croce CM, Chan DA, Giaccia AJ, Secreto C, Wellik LE, Lee YK, Mukhopadhyay D, Kay NE. Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood 2009 May 28; 113(22):5568-74. Epub 2009 Mar 31.
    View PubMed
13. Shanafelt TD, Kay NE, Jenkins G, Call TG, Zent CS, Jelinek DF, Morice WG, Boysen J, Zakko L, Schwager S, Slager SL, Hanson CA. B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood 2009 Apr 30; 113(18):4188-96. Epub 2008 Nov 17.
    View PubMed
14. Nowakowski GS, Hoyer JD, Shanafelt TD, Zent CS, Call TG, Bone ND, Laplant B, Dewald GW, Tschumper RC, Jelinek DF, Witzig TE, Kay NE. Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia. J Clin Oncol 2009 Apr 10; 27(11):1844-9. Epub 2009 Mar 02.
    View PubMed
15. Kay NE, Shanafelt TD, Call TG, Wu W, Laplant BR. N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia. Leuk Lymphoma 2009 Apr; 50(4):588-92.
    View PubMed
16. Messmer BT, Raphael BJ, Aerni SJ, Widhopf GF, Rassenti LZ, Gribben JG, Kay NE, Kipps TJ. Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res 2009 Mar; 33(3):368-76. Epub 2008 Jul 21.
    View PubMed
17. Ghosh AK, Kay NE, Secreto CR, Shanafelt TD. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res 2009 Feb 15; 15(4):1250-8.
    View PubMed
18. Shanafelt TD, Bowen DA, Venkat C, Slager SL, Zent CS, Kay NE, Reinalda M, Tun H, Sloan JA, Call TG. The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia. Leuk Res 2009 Feb; 33(2):263-70. Epub 2008 Jul 25.
    View PubMed
19. Awan, FT, Kay NE, Davis ME, Wu W, Geyer SM, Leung, N, Jelinek DF, Tschumper RC, Secreto CR, Lin TS, Grever MR, Shanafelt TD, Zent CS, Call TG, Heerema NA, Lozanski G, Byrd JC, Lucas DM. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood 2009 Jan 15; 113(3):535-7.
    View PubMed
20. Shanafelt TD, Jenkins G, Call TG, Zent CS, Slager S, Bowen DA, Schwager S, Hanson CA, Jelinek DF, Kay NE. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 2009 Jan 15; 115(2):363-72.
    View PubMed
21. Kay NE, Shanafelt TD, Call TG, Wu WT, Laplant BR. N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50(4):588-92.
    View PubMed
22. Zent CS, Ding W, Reinalda MS, Schwager SM, Hoyer JD, Bowen DA, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Kay NE, Slager SL. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leuk Lymphoma 2009; 50(8):1261-8.
    View PubMed
23. Slager SL, Kay NE. Familial chronic lymphocytic leukemia: what does it mean to me? Clin Lymphoma Myeloma 2009; 9 Suppl 3:S194-7.
    View PubMed
24. Zent CS, Secreto CR, LaPlant BR, Bone ND, Call TG, Shanafelt TD, Jelinek DF, Tschumper RC, Kay NE. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res 2008 Dec; 32(12):1849-56. Epub 2008 Jun 27.
    View PubMed
25. Cerhan JR, Liu-Mares W, Fredericksen ZS, Novak AJ, Cunningham JM, Kay NE, Dogan A, Liebow M, Wang AH, Call TG, Habermann TM, Ansell SM, Slager SL. Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2008 Nov; 17(11):3161-9.
    View PubMed
26. Zent CS, Call TG, Shanafelt TD, Tschumper RC, Jelinek DF, Bowen DA, Secreto CR, Laplant BR, Kabat BF, Kay NE. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 2008 Oct 15; 113(8):2110-8.
    View PubMed
27. Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008 Sep 1; 112(5):1923-30.
    View PubMed
28. Shanafelt TD, Kay NE, Call TG, Zent CS, Jelinek DF, LaPlant B, Morice WG, Hanson CA. MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)? Leuk Res 2008 Sep; 32(9):1458-61. Epub 2008 Jan 07.
    View PubMed
29. Ghia EM, Jain S, Widhopf GF 2nd, Rassenti LZ, Keating MJ, Wierda WG, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood 2008 May 15; 111(10):5101-8. Epub 2008 Mar 07.
    View PubMed
30. Shanafelt TD, Hanson C, Dewald GW, Witzig TE, LaPlant B, Abrahamzon J, Jelinek DF, Kay NE. Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. J Clin Oncol 2008 May 10; 26(14):e5-6.
    View PubMed
31. Palmer S, Hanson CA, Zent CS, Porrata LF, Laplant B, Geyer SM, Markovic SN, Call TG, Bowen DA, Jelinek DF, Kay NE, Shanafelt TD. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol 2008 May; 141(5):607-14. Epub 2008 Apr 01.
    View PubMed
32. Zent CS, Ding W, Schwager SM, Reinalda MS, Hoyer JD, Jelinek DF, Tschumper RC, Bowen DA, Call TG, Shanafelt TD, Kay NE, Slager SL. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol 2008 May; 141(5):615-21. Epub 2008 Mar 27.
    View PubMed
33. Nabhan C, Shanafelt TD, Kay NE. Controversies in the front-line management of chronic lymphocytic leukemia. Leuk Res 2008 May; 32(5):679-88. Epub 2008 Jan 11.
    View PubMed
34. Shanafelt TD, Geyer SM, Bone ND, Tschumper RC, Witzig TE, Nowakowski GS, Zent CS, Call TG, Laplant B, Dewald GW, Jelinek DF, Kay NE. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol 2008 Mar; 140(5):537-46.
    View PubMed
35. Thurmes P, Call T, Slager S, Zent C, Jenkins G, Schwager S, Bowen D, Kay N, Shanafelt T. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008 Jan; 49(1):49-56.
    View PubMed
36. Tschumper RC, Geyer SM, Campbell ME, Kay NE, Shanafelt TD, Zent CS, Nowakowski GS, Call TG, Dewald GW, Jelinek DF. Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients. J Clin Invest 2008 Jan; 118(1):306-15.
    View PubMed
37. Frater JL, Kay NE, Goolsby CL, Crawford SE, Dewald GW, Peterson LC. Dysregulated angiogenesis in B-chronic lymphocytic leukemia: Morphologic, immunohistochemical, and flow cytometric evidence. Diagn Pathol 2008; 3:16. Epub 2008 Apr 18.
    View PubMed
38. Cerhan JR, Ansell SM, Fredericksen ZS, Kay NE, Liebow M, Call TG, Dogan A, Cunningham JM, Wang AH, Liu-Mares W, Macon WR, Jelinek D, Witzig TE, Habermann TM, Slager SL. Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood 2007 Dec 15; 110(13):4455-63. Epub 2007 Sep 07.
    View PubMed
39. Browning RL, Geyer SM, Johnson AJ, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC, Lucas DM. Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. Leuk Res 2007 Dec; 31(12):1737-40. Epub 2007 Jul 19.
    View PubMed
40. Slager SL, Kay NE, Fredericksen ZS, Wang AH, Liebow M, Cunningham JM, Vachon CM, Call TG, Cerhan JR. Susceptibility genes and B-chronic lymphocytic leukaemia. Br J Haematol 2007 Dec; 139(5):762-71.
    View PubMed
41. Bowen DA, Call TG, Jenkins GD, Zent CS, Schwager SM, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007 Dec; 48(12):2412-7.
    View PubMed
42. Maddocks-Christianson K, Slager SL, Zent CS, Reinalda M, Call TG, Habermann TM, Bowen DA, Hoyer JD, Schwager S, Jelinek DF, Kay NE, Shanafelt TD. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol 2007 Nov; 139(3):398-404.
    View PubMed
43. Shanafelt TD, Bowen D, Venkat C, Slager SL, Zent CS, Kay NE, Reinalda M, Sloan JA, Call TG. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol 2007 Oct; 139(2):255-64.
    View PubMed
44. Zent CS, Kay NE. Chronic lymphocytic leukemia: biology and current treatment. Curr Oncol Rep 2007 Sep; 9(5):345-52.
    View PubMed
45. Kay NE, O'Brien SM, Pettitt AR, Stilgenbauer S. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia 2007 Sep; 21(9):1885-91. Epub 2007 Jun 14.
    View PubMed
46. Ougolkov AV, Bone ND, Fernandez-Zapico ME, Kay NE, Billadeau DD. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 2007 Jul 15; 110(2):735-42. Epub 2007 Apr 26.
    View PubMed
47. Kay NE, Shanafelt TD, Strege AK, Lee YK, Bone ND, Raza A. Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". Leuk Res 2007 Jul; 31(7):899-906. Epub 2007 Jan 22.
    View PubMed
48. Shanafelt TD, Lin T, Geyer SM, Zent CS, Leung N, Kabat B, Bowen D, Grever MR, Byrd JC, Kay NE. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007 Jun 1; 109(11):2291-8.
    View PubMed
49. Martin W, Abraham R, Shanafelt T, Clark RJ, Bone N, Geyer SM, Katzmann JA, Bradwell A, Kay NE, Witzig TE. Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Transl Res 2007 Apr; 149(4):231-5.
    View PubMed
50. Nowakowski GS, Hoyer JD, Shanafelt TD, Geyer SM, LaPlant BR, Call TG, Jelinek DF, Zent CS, Kay NE. Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test. Mayo Clin Proc 2007 Apr; 82(4):449-53.
    View PubMed
51. Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, Tschumper R, Bone ND, Dewald GW, Lin TS, Heerema NA, Smith L, Grever MR, Byrd JC. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007 Jan 15; 109(2):405-11. Epub 2006 Sep 28.
    View PubMed
52. Mukherjee P, Bhattacharya R, Bone N, Lee YK, Patra CR, Wang S, Lu L, Secreto C, Banerjee PC, Yaszemski MJ, Kay NE, Mukhopadhyay D. Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis. J Nanobiotechnology 2007; 5:4. Epub 2007 May 08.
    View PubMed
53. Shanafelt TD, Kay NE. Comprehensive management of the CLL patient: a holistic approach. Hematology Am Soc Hematol Educ Program 2007; 324-31.
    View PubMed
54. Kay NE, Rai KR, O'Brien S. Chronic lymphocytic leukemia: current and emerging treatment approaches. Clin Adv Hematol Oncol 2006 Nov; 4(11 Suppl 22):1-10; quiz 11-2.
    View PubMed
55. Chng WJ, Schop RF, Price-Troska T, Ghobrial I, Kay N, Jelinek DF, Gertz MA, Dispenzieri A, Lacy M, Kyle RA, Greipp PR, Tschumper RC, Fonseca R, Bergsagel PL. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 2006 Oct 15; 108(8):2755-63. Epub 2006 Jun 27.
    View PubMed
56. Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, Stockero KJ, Nast DM, Flynn HC, Tschumper RC, Geyer S, Zent CS, Call TG, Jelinek DF, Kay NE, Dewald GW. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006 Oct 1; 24(28):4634-41.
    View PubMed
57. Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med 2006 Sep 19; 145(6):435-47.
    View PubMed
58. Zent CS, Call TG, Hogan WJ, Shanafelt TD, Kay NE. Update on risk-stratified management for chronic lymphocytic leukemia. Leuk Lymphoma 2006 Sep; 47(9):1738-46.
    View PubMed
59. Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE, Carter CA, Roberts LR, Kaufmann SH, Adjei AA. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther 2006 Sep; 5(9):2378-87.
    View PubMed
60. Shanafelt T, Kay N. T-cell abnormalities in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2006 Jul; 47(7):1197-8.
    View PubMed
61. Fink SR, Smoley SA, Stockero KJ, Paternoster SF, Thorland EC, Van Dyke DL, Shanafelt TD, Zent CS, Call TG, Kay NE, Dewald GW. Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia. Cancer Genet Cytogenet 2006 Jun; 167(2):177-81.
    View PubMed
62. Shanafelt TD, Lee YK, Call TG, Nowakowski GS, Dingli D, Zent CS, Kay NE. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res 2006 Jun; 30(6):707-12. Epub 2005 Dec 01.
    View PubMed
63. Kyle RA, Leong T, Li S, Oken MM, Kay NE, Van Ness B, Greipp PR. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer 2006 May 1; 106(9):1958-66.
    View PubMed
64. Stockero KJ, Fink SR, Smoley SA, Paternoster SF, Shanafelt TD, Call TG, Zent CS, Van Dyke DL, Kay NE, Dewald GW. Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 2006 Apr 15; 166(2):152-6.
    View PubMed
65. Kay NE. Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia. Semin Hematol 2006 Apr; 43(2 Suppl 2):S50-4.
    View PubMed
66. Shanafelt TD, Kay NE. The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Semin Oncol 2006 Apr; 33(2):174-85.
    View PubMed
67. Novak AJ, Grote DM, Ziesmer SC, Kline MP, Manske MK, Slager S, Witzig TE, Shanafelt T, Call TG, Kay NE, Jelinek DF, Cerhan JR, Gross JA, Harder B, Dillon SR, Ansell SM. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006 Feb 20; 24(6):983-7. Epub 2006 Jan 23.
    View PubMed
68. Pittner BT, Shanafelt TD, Kay NE, Jelinek DF. CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation. Leukemia 2005 Dec; 19(12):2264-72.
69. Kay NE, Bone ND, Lee YK, Jelinek DF, Leland P, Battle TE, Frank DA, Puri RK. A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells. Leuk Res 2005 Sep; 29(9):1009-18.
    View PubMed
70. Marti GE, Rawstron AC, Ghia P, Hillmen P, Houlston RS, Kay N, Schleinitz TA, Caporaso N. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol 2005 Aug; 130(3):325-32.
    View PubMed
71. Barnidge DR, Jelinek DF, Muddiman DC, Kay NE. Quantitative protein expression analysis of CLL B cells from mutated and unmutated IgV(H) subgroups using acid-cleavable isotope-coded affinity tag reagents. J Proteome Res 2005 Jul-Aug; 4(4):1310-7.
    View PubMed
72. Nowakowski GS, Dewald GW, Hoyer JD, Paternoster SF, Stockero KJ, Fink SR, Smoley SA, Remstein ED, Phyliky RL, Call TG, Shanafelt TD, Kay NE, Zent CS. Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia. Br J Haematol 2005 Jul; 130(1):36-42.
    View PubMed
73. Nolz JC, Tschumper RC, Pittner BT, Darce JR, Kay NE, Jelinek DF. ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. Leukemia 2005 Jun; 19(6):1018-24.
    View PubMed
74. Barnidge DR, Tschumper RC, Jelinek DF, Muddiman DC, Kay NE. Protein expression profiling of CLL B cells using replicate off-line strong cation exchange chromatography and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2005 May 5; 819(1):33-9.
75. Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia 2005 Apr; 19(4):513-23.
    View PubMed
76. Shanafelt TD, Lee YK, Bone ND, Strege AK, Narayanan VL, Sausville EA, Geyer SM, Kaufmann SH, Kay NE. Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. Blood 2005 Mar 1; 105(5):2099-106. Epub 2004 Sep 23.
    View PubMed
77. Fink SR, Paternoster SF, Smoley SA, Flynn HC, Geyer SM, Shanafelt TD, Lee YK, Jelinek DF, Kay NE, Dewald GW. Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia. Leuk Res 2005 Mar; 29(3):253-62.
    View PubMed
78. Zent CS, Kay NE. Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia. Curr Oncol Rep 2004 Sep; 6(5):348-54.
    View PubMed
79. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004 Aug 26; 351(9):893-901.
    View PubMed
80. Ghobrial IM, Bone ND, Stenson MJ, Novak A, Hedin KE, Kay NE, Ansell SM. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. Mayo Clin Proc 2004 Mar; 79(3):318-25.
    View PubMed
81. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004 Feb 15; 103(4):1202-10. Epub 2003 Oct 23.
    View PubMed
82. Zent CS, Kay NE. Update on monoclonal antibody therapy in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2004 Feb; 2(2):107-13.
    View PubMed
83. Oken MM, Lee S, Kay NE, Knospe W, Cassileth PA. Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488. Leuk Lymphoma 2004 Jan; 45(1):79-84.
    View PubMed
84. Chandra J, Hackbarth J, Le S, Loegering D, Bone N, Bruzek LM, Narayanan VL, Adjei AA, Kay NE, Tefferi A, Karp JE, Sausville EA, Kaufmann SH. Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood 2003 Dec 15; 102(13):4512-9. Epub 2003 Aug 14.
    View PubMed
85. Kay NE, Pittner BT. IL-4 biology: impact on normal and leukemic CLL B cells. Leukemia & Lymphoma 2003 Jun; 44(6):897-903.
    View PubMed
86. Dewald GW, Brockman SR, Paternoster SF, Bone ND, O'Fallon JR, Allmer C, James CD, Jelinek DF, Tschumper RC, Hanson CA, Pruthi RK, Witzig TE, Call TG, Kay NE. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003 Apr; 121(2):287-95.
    View PubMed
87. Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu YH, Lepre J, Shah N, Kay NE. Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Molecular Cancer Research: MCR 2003 Mar; 1(5):346-61.
    View PubMed
88. Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002 Oct 15; 100(8):2973-9.
    View PubMed
89. Cerhan JR, Janney CA, Vachon CM, Habermann TM, Kay NE, Potter JD, Sellers TA, Folsom AR. Anthropometric characteristics, physical activity, and risk of non-Hodgkin's lymphoma subtypes and B-cell chronic lymphocytic leukemia: A prospective study. Am J Epidemiol 2002 Sep 15; 156(6):527-35.
    View PubMed
90. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Hoyer JD, Harrington D, Kay NE, Van Ness B, Greipp PR. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002 May 15; 99(10):3735-41.
    View PubMed
91. Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW, Hanson CA, Jelinek DF. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 2002 May; 16(5):911-9.
    View PubMed
92. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Blood EA, Rajkumar SV, Kay NE, Van Ness B, Greipp PR. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (Delta 13) in multiple myeloma: An Eastern Cooperative Oncology Group study. Cancer Res 2002 Feb 1; 62(3):715-20.
    View PubMed
93. Kay NE, Hamblin TJ, Jelinek DF, Dewald GW, Byrd JC, Farag S, Lucas M, Lin T. Chronic lymphocytic leukemia. Hematol 2002; 193-213.
94. Cerhan JR, Janney CA, Vachon CM, Habermann TM, Kay NE, Potter JD, Sellers TA, Folsom AR. A prospective study of anthropometric factors, physical activity, and risk of non-Hodgkin lymphoma subtypes and chronic lymphocytic leukemia. Am J Epidemiol 2002; 156:527-35.
    View PubMed
95. Kay NE, Bone ND, Tschumper RC, Howell KH, Jelinek DF. Angiogenic status of blood B cells in B-chronic lymphocytic leukemia. Leukemia 2002; 16:911-9.
    View PubMed
96. Jelinek DF, Tschumper RC, Geyer SM, Bone ND, Dewald GW, Hanson CA, Stenson MJ, Witzig TE, Tefferi A, Kay NE. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001 Dec; 115(4):854-61.
    View PubMed
97. Kay NE, Jelinek DF, Peterson LA. Angiogenesis in B-chronic lymphocytic leukemia. Leuk Res 2001 Aug; 25(8):709-10.
    View PubMed
98. Kay NE, Leong TL, Bone N, Vesole DH, Greipp PR, Van Ness B, Oken MM, Kyle RA. Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood 2001 Jul 1; 98(1):23-8.
    View PubMed
99. Fonseca R, Oken MM, Harrington D, Bailey RJ, Van Wier SA, Henderson KJ, Kay NE, Van Ness B, Greipp PR, Dewald GW. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 2001 Jun; 15(6):981-6.
    View PubMed
100. Kay NE, Jelinek DF, Peterson L. Angiogenesis in B-chronic lymphocytic leukemia. Leuk Res 2001 Jun; 25(6):485-6.
     View PubMed
101. Kay NE, Han L, Bone N, Williams G. Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis. Br J Haematol 2001 Mar; 112(3):760-7.
     View PubMed
102. Hogan WJ, Kay NE. 87-year-old man with macrocytic anemia. Mayo Clin Proc 2001 Feb; 76(2):201-4.
     View PubMed
103. Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 2000 Aug; 14(8):1414-8.
     View PubMed
104. Fonseca R, Trendle MC, Leong T, Kyle RA, Oken MM, Kay NE, Van Ness B, Greipp PR. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol 2000 Apr; 109(1):24-9.
     View PubMed
105. Oken MM, Leong T, Lenhard RE Jr, Greipp PR, Kay NE, Van Ness B, Keimowitz RM, Kyle RA. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Cancer 1999 Sep 15; 86(6):957-68.
     View PubMed
106. Greipp PR, Trendle MC, Leong T, Oken MM, Kay NE, Van Ness B, Kyle RA. Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leukemia & Lymphoma 1999 Sep; 35(1-2):83-9.
     View PubMed
107. Trendle MC, Leong T, Kyle RA, Katzmann JA, Oken MM, Kay NE, Van Ness BG, Greipp PR. Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486. Am J Hematol 1999 Aug; 61(4):232-7.
     View PubMed
108. Orel SG, Kay N, Reynolds C, Sullivan DC. BI-RADS categorization as a predictor of malignancy. Radiology 1999 Jun; 211(3):845-50.
     View PubMed
109. Kay N, Leong T, Kyle RA, Greipp P, Van Ness B, Bone N, Oken MM. Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a Study of the Eastern Cooperative Oncology Group (E9487). Leukemia & Lymphoma 1999 Mar; 33(1-2):127-33.
     View PubMed
110. Mu XY, Gosland MP, Bartik MM, Schimmelpfennig J, Kay NE. Activation of human peripheral blood T cells does not lead to increased P-glycoprotein expression. Journal of Clinical Immunology 1999; 19(4):239-46.
     View PubMed
111. Finn WG, Kay NE, Kroft SH, Church S, Peterson LC. Secondary abnormalities of chromosome 6q in B-cell chronic lymphocytic leukemia: a sequential study of karyotypic instability in 51 patients. Am J Hematol 1998 Nov; 59(3):223-9.
     View PubMed
112. Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA, Oken MM, Kay NE, Van Ness B, Kyle RA. Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 1998 Apr 1; 91(7):2501-7.
     View PubMed
113. Kay NE, Leong T, Bone N, Kyle RA, Greipp PR, Van Ness B, Oken MM. T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93. Br J Haematol 1998 Mar; 100(3):459-63.
     View PubMed
114. Bartik MM, Welker D, Kay NE. Impairments in immune cell function in B cell chronic lymphocytic leukemia. Semin Oncol 1998 Feb; 25(1):27-33.
     View PubMed
115. Kay NE, Leong T, Kyle RA, Greipp P, Billadeau D, Van Ness B, Bone N, Oken MM. Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial. Blood 1997 Jul 1; 90(1):340-5.
     View PubMed
116. Mu X, Kay NE, Gosland MP, Jennings CD. Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukaemia: evidence for increased levels of cytoplasmic IL-4 in resting and activated CD8 T cells. Br J Haematol 1997 Mar; 96(4):733-5.
     View PubMed
117. Kroft SH, Finn WG, Kay NE, Peterson LC. Isolated 13q14 abnormalities and normal karyotypes are associated with typical lymphocyte morphology in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 1997 Mar; 107(3):275-82.
     View PubMed
118. Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, Kyle RA, Oken MM, Van Ness B. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 1996 Oct 1; 88(7):2699-706.
     View PubMed
119. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996 Jun 15; 87(12):4990-7.
     View PubMed
120. Kay NE. Clinical utility of molecular probes in lymphoproliferative disorders. Blood Rev 1996 Jun; 10(2):81-8.
     View PubMed
121. Oken MM, Kyle RA, Greipp PR, Kay NE, Tsiatis A, Gregory SA, Spiegel RJ, Oconnell MJ. Complete remission induction with combined VBCMP chemotherapy and interferon (rIFN(alpha-2B)) in patients with multiple myeloma. Leuk Lymphoma 1996 Feb; 20(5-6):447-452.
     View PubMed
122. Kay NE, Ranheim EA, Peterson LC. Tumor suppressor genes and clonal evolution in B-CLL. Leukemia & Lymphoma 1995 Jun; 18(1-2):41-9.
     View PubMed
123. Kay NE, Oken MM, Kyle R, Van Ness B, Kalish L, Leong T, Greipp P. Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cells. Leukemia & Lymphoma 1995 Jan; 16(3-4):351-4.
     View PubMed
124. Kay NE, Oken MM, Bone N, Kyle RA, Greipp PR, Van Ness B, Leong T. Circulating CD+19 Blood Cell Levels in Myeloma. Blood 1995; 86(10):4000-1.
     View PubMed
125. Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clinical & Diagnostic Laboratory Immunology 1994 Jul; 1(4):365-72.
     View PubMed
126. Burton J, Kay NE. Does IL-2 receptor expression and secretion in chronic B-cell leukemia have a role in down-regulation of the immune system? Leukemia 1994 Jan; 8(1):92-6.
     View PubMed
127. Hings I, Kay NE, Ranheim E, Seroogy C, Parson RE. Malignant B cell CD5 membrane phenotype and B cell colony growth in vivo and in vitro in patients with B-chronic lymphocytic leukemia: analysis with clinical parameters. Leukemia & Lymphoma 1993 Dec; 12(1-2):59-67.
     View PubMed
128. Christie DJ, Sauro SC, Fairbanks KD, Kay NE. Detection of clonal platelet antibodies in immunologically-mediated thrombocytopenias: association with circulating clonal/oligoclonal B cells. Br J Haematol 1993 Oct; 85(2):277-84.
     View PubMed
129. Kay NE, Suen R, Ranheim E, Peterson LC. Confirmation of Rb gene defects in B-CLL clones and evidence for variable predominance of the Rb defective cells within the CLL clone. Br J Haematol 1993 Jun; 84(2):257-64.
     View PubMed
130. Billadeau D, Quam L, Thomas W, Kay N, Greipp P, Kyle R, Oken MM, Van Ness B. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992 Oct 1; 80(7):1818-24.
     View PubMed
131. Zaknoen SL, Christian SL, Suen R, Van Ness B, Kay NE. B-chronic lymphocytic leukemia cells contain both endogenous kappa immunoglobulin mRNA and critical immunoglobulin gene activation transcription factors. Leukemia 1992 Jul; 6(7):675-9.
     View PubMed
132. Peterson LC, Lindquist LL, Church S, Kay NE. Frequent clonal abnormalities of chromosome band 13q14 in B-cell chronic lymphocytic leukemia: multiple clones, subclones, and nonclonal alterations in 82 midwestern patients. Genes, Chromosomes & Cancer 1992 Jun; 4(4):273-80.
     View PubMed
133. Redmon B, Pyzdrowski KL, Elson MK, Kay NE, Dalmasso AP, Nuttall FQ. Hypoglycemia due to an insulin-binding monoclonal antibody in multiple myeloma. N Engl J Med 1992 Apr 9; 326(15):994-8.
     View PubMed
134. Billadeau D, Blackstadt M, Greipp P, Kyle RA, Oken MM, Kay N, Van Ness B. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease. Blood 1991 Dec 1; 78(11):3021-9.
     View PubMed
135. Juliusson G, Gahrton G, Oscier D, Fitchett M, Ross F, Brito-Babapulle V, Catovsky D, Knuutila S, Elonen E, Lechleitner M, Tanzer J, Schoenwald M, Castoldi GL, Cuneo A, Nowell P, Peterson L, Kay NE. Cytogenetic finding and survival in B-cell chronic lymphocytic leukemia. second IWCCL compilation of data on 662 patients. Leuk Lymphoma 1991; (Suppl):21-5.
136. Kay NE, Peterson L. Heterogeneity of CD5 membrane expression on B-chronic lymphocytic leukemia cells. Leuk Lymphoma 1991; 5:49-55.
137. Zaknoen SL, Kay NE. Immunoregulatory cell dysfunction in chronic B-cell leukemias. Blood Rev 1990 Sep; 4(3):165-74.
     View PubMed
138. Kay NE, Morley JE, Allen JI. Interaction between endogenous opioids and IL-2 on PHA-stimulated human lymphocytes. Immunology 1990 Aug; 70(4):485-91.
     View PubMed
139. Verfaillie C, Kay N, Miller W, McGlave P. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. Blood 1990 Jul 15; 76(2):401-8.
     View PubMed
140. Kay NE, Bone N, Hupke M, Dalmasso AP. Expansion of a lymphocyte population co-expressing T4 (CD4) and T8 (CD8) antigens in the peripheral blood of a normal adult male. Blood 1990 May 15; 75(10):2024-9.
     View PubMed
141. Kay NE. Immune regulation of myeloma cells. Clinical Immunology Newsletter 1990; 10(6):79.
142. Oken MM, Kyle RA, Kay NE, Greipp PR, O'Connell MJ. Interferon in the treatment of refractory multiple myeloma: an Eastern Cooperative Oncology Group study. Leuk Lymphoma 1990; 1:95-100.
143. Verfaillie C, Miller W, Kay N, McGlave P. Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity. Blood 1989 Aug 1; 74(2):793-7.
     View PubMed
144. Perri RT, Kay NE. Large granular lymphocytes from B-chronic lymphocytic leukemia patients inhibit normal B cell proliferation. Am J Hematol 1989 Jul; 31(3):166-72.
     View PubMed
145. Kay NE, Perri RT. Evidence that large granular lymphocytes from B-CLL patients with hypogammaglobulinemia down-regulate B-cell immunoglobulin synthesis. Blood 1989 Mar; 73(4):1016-9.
     View PubMed
146. Burton JD, Weitz CH, Kay NE. Malignant chronic lymphocytic leukemia B cells elaborate soluble factors that down-regulate T cell and NK function. Am J Hematol 1989 Feb; 30(2):61-7.
     View PubMed
147. Mandel JS, Berlinger NT, Kay N, Connett J, Reape M 3rd. Organophosphate exposure inhibits non-specific esterase staining in human blood monocytes. Am J Ind Med 1989; 15(2):207-12.
     View PubMed
148. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Oken MM, Schiffer CA, Keating MJ, Boldt DH, Kempin SJ, et al. Chronic lymphocytic leukemia: recommendations. Annals of Internal Medicine , 1989; 110(8):664-5.
149. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 1988 Nov; 29(3):152-63.
     View PubMed
150. Mladenovic J, Kay NE. Erythropoietin induces rapid increases in intracellular free calcium in human bone marrow cells. J Lab Clin Med 1988 Jul; 112(1):23-7.
     View PubMed
151. Kay NE, Perri RT. Immunobiology of malignant B cells and immunoregulatory cells in B-chronic lymphocytic leukemia. Clin Lab Med 1988 Mar; 8(1):163-77.
     View PubMed
152. Kay NE, Oken MM, Mazza JJ, Bradley EC. Evidence for tumor reduction in refractory or relapsed B-CLL patients with infusional interleukin-2. Nouv Rev Fr Hematol 1988; 30(5-6):475-8.
153. Kay NE, Perri RT. Natural killer function in B-chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988; 30(5-6):343-5.
154. Cavanaugh J, Kay NE, Binimelis J, de Leiva A, Barbosa J. A new marker of T lymphocyte activation in type I diabetes. Adv Exp Med Biol 1988; 246:79-84.
     View PubMed
155. Kay NE, Burton J, Wagner D, Nelson DL. The malignant B cells from B-chronic lymphocyti leukemia patients release TAC-soluble interleukin-2 receptors. Blood 1988; 72(2):447-50.
     View PubMed
156. Morley JE, Kay NE, Solomon GF, Plotnikoff NP. Neuropeptides: conductors of the immune orchestra. Life Sci 1987 Aug 3; 41(5):527-44.
     View PubMed
157. Allen JI, Syropoulos HJ, Grant B, Eagon JC, Kay NE. Cimetidine modulates natural killer cell function of patients with chronic lymphocytic leukemia. Journal of Laboratory & Clinical Medicine 1987 Apr; 109(4):396-401.
     View PubMed
158. Kay NE, Raij L. Differential effect of hemodialysis membranes on human lymphocyte natural killer function. Artif Organs 1987 Apr; 11(2):165-7.
     View PubMed
159. Kay N, Morley JE, van Ree JM. Enhancement of human lymphocyte natural killing function by non-opioid fragments of beta-endorphin. Life Sci 1987 Mar 16; 40(11):1083-7.
     View PubMed
160. Kay NE, Zarling J. Restoration of impaired natural killer cell activity of B-chronic lymphocytic leukemia patients by recombinant interleukin-2. Am J Hematol 1987 Feb; 24(2):161-7.
     View PubMed
161. Raij L, Kay NE. Effect of hemodialysis membranes on human lymphocyte natural killer function. Contrib Nephrol 1987; 59:17-25.
     View PubMed
162. Perri RT, Kay NE. Malignant chronic lymphocytic leukemia B cells express interleukin-2 receptors but fail to respond to interleukin-2's proliferative signal. Leukemia 1987; 1(2):127-30.
     View PubMed
163. Perri RT, Wilson BS, Kay NE. Inhibition of B cell growth factor (BCGF) by monoclonal antibodies directed against the C3d receptor (CR2). Eur J Immunol 1986 Apr; 16(4):350-5.
     View PubMed
164. Allen JI, Ferrone S, Boue D, Kay NE. The monoclonal antibody CJA3 down-regulates the susceptibility of human tumor cell lines to natural cell-mediated cytotoxicity. J Immunol 1986 Mar 15; 136(6):2318-22.
     View PubMed
165. Kay NE, Kaplan ME. Defective T cell responsiveness in chronic lymphocytic leukemia: analysis of activation events. Blood 1986 Mar; 67(3):578-81.
     View PubMed
166. O'Connell MJ, Colgan JP, Oken MM, Ritts RE Jr, Kay NE, Itri LM. Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1986 Feb; 4(2):128-36.
     View PubMed
167. Kay NE. Natural killer cells. Crit Rev Clin Lab Sci 1986; 22(4):343-59.
     View PubMed
168. Ascensao JL, Kay NE, Wright JJ, Arthur D, Finkel B, Rydell R, Kaplan ME. Lymphoblastic transformation of myelodysplastic syndrome. American Journal of Hematology 1986; 22(4):431-4.
     View PubMed
169. Kay N, Markham PD. Chronic Lymphocytic Leukemia: an AIDS like disease? British Journal of Haematology 1986; 63(2):389-91.
     View PubMed
170. Perri RT, Kay NE. Abnormal T cell function in early-stage chronic lymphocytic leukemia (CLL) patients. American J of Hematology , 1986; 22(1):55-61.
171. Kay NE, Raij LR. Immune abnormalities in renal failure and hemodialysis. Blood Purif 1986; 4(1-3):120-9.
     View PubMed
172. Grant BW, Platt JL, Jacob HS, Kay NE. Lymphocyte populations and TAC-antigen in diffuse B-cell lymphomas. Leuk Res 1986; 10(11):1271-8.
     View PubMed
173. Wilson BS, Platt JL, Kay NE. Monoclonal antibodies to the 140,000 mol wt glycoprotein of B lymphocyte membranes (CR2 receptor) initiates proliferation of B cells in vitro. Blood 1985 Oct; 66(4):824-9.
     View PubMed
174. Hammerschmidt DE, Goldberg R, Raij L, Kay NE. Leukocyte abnormalities in renal failure and hemodialysis. Semin Nephrol 1985 Jun; 5(2):91-103.
     View PubMed
175. Ibele GM, Kay NE, Johnson GJ, Jacob HS. Human platelets exert cytotoxic effects on tumor cells. Blood 1985 May; 65(5):1252-5.
     View PubMed
176. McClain K, Warkentin P, Kay N. Spontaneous remission of Burkitt's lymphoma associated with herpes zoster infection. Am J Pediatr Hematol Oncol 1985 Spring; 7(1):9-14.
     View PubMed
177. Morley JE, Kay N, Allen J, Moon T, Billington CJ. Endorphins, immune function, and cancer. Psychopharmacol Bull 1985; 21(3):485-8.
     View PubMed
178. Perri RT, Allen JI, Oken MM, Limas C, Kay NE. Simultaneous presentation of relapsing Hodgkin's disease and treatment-related non-Hodgkin's lymphoma. Medical & Pediatric Oncology 1985; 13(3):122-5.
     View PubMed
179. Kay NE, Oken MM, Ascensao J, Kaplan ME. Lymphocytotoxic T lymphocytes in a patient with B-chronic lymphocytic leukemia and pure red cell aplasia. Leuk Res 1985; 9(9):1189-94.
     View PubMed
180. Kay N, Allen J, Morley JE. Endorphins stimulate normal human peripheral blood lymphocyte natural killer activity. Life Sci 1984 Jul 2; 35(1):53-9.
     View PubMed
181. Kay NE, Kaplan ME. Defective expression of T cell antigens in chronic lymphocytic leukaemia: relationship to T cell dysfunction. Br J Haematol 1984 May; 57(1):105-11.
     View PubMed
182. Kay NE, Zarling JM. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 1984 Feb; 63(2):305-9.
     View PubMed
183. Peacock TE, Kay NE, Ascensao JL, Kaplan ME. Establishment and characterization of a subclone (U-937-AG) from a permanent human monocyte cell line. Leuk Res 1984; 8(3):435-9.
     View PubMed
184. Kay NE, Oken MM, Perri RT. The influential T cell in B-cell neoplasms. J Clin Oncol 1983 Dec; 1(12):810-6.
     View PubMed
185. Perri RT, Royston I, LeBien TW, Kay NE. Chronic lymphocytic leukemia progenitor cells carry the antigens T65, BA-1, and Ia. Blood 1983 May; 61(5):871-5.
     View PubMed
186. Zarling JM, Kay NE, Grant B, Yasukawa M, Bach FH. Human anti-lymphoma responses generated in vitro and in vivo following sensitization with allogeneic leukocytes. Cancer Immunol Immunother 1983; 15(3):237-9.
     View PubMed
187. Kay NE, Johnson J, Douglas SD. Effects of human T-cell subpopulations on B-cell proliferation as determined by (3H)-thymidine incorporation. Diagn Immunol 1983; 1(1):11-6.
     View PubMed
188. Allen JI, Perri RT, McClain CJ, Kay NE. Alterations in human natural killer cell activity and monocyte cytotoxicity induced by zinc deficiency. J Lab Clin Med 1983; 102(4):577-89.
     View PubMed
189. Allen JI, Korchik W, Kay NE, McClain CJ. Zinc and T-lymphocyte function in hemodialysis patients. Am J Clin Nutr 1982 Sep; 36(3):410-5.
     View PubMed
190. Perri RT, Kay NE, McCarthy J, Vessella RL, Jacob HS, Furcht LT. Fibronectin enhances in vitro monocyte-macrophage-mediated tumoricidal activity. Blood 1982 Aug; 60(2):430-5.
     View PubMed
191. Kay NE, Holloway DE, Hutton SW, Bone ND, Duane WC. Human T-cell function in experimental ascorbic acid deficiency and spontaneous scurvy. Am J Clin Nutr 1982 Jul; 36(1):127-30.
     View PubMed
192. Perri RT, Oken MM, Kay NE. Enhanced T cell suppression is directed toward sensitive circulating B cells in multiple myeloma. Journal of Laboratory & Clinical Medicine 1982 Apr; 99(4):512-9.
     View PubMed
193. Perri RT, Kay NE. Monoclonal CLL B-cells may be induced to grow in an in vitro B-cell colony assay system. Blood 1982 Feb; 59(2):247-9.
     View PubMed
194. Wilson BS, Kay NE, Imai K, Ferrone S. Heterogeneity of human melanoma-associated antigens defined by monoclonal antibodies and conventional xenoantisera. Cancer Immunol Immunother 1982; 13(1):69-74.
     View PubMed
195. Kay NE, Howe RB, Douglas SD. Effect of therapy on T cell subpopulations in patients with chronic lymphocytic leukemia. Leuk Res 1982; 6(3):345-8.
     View PubMed
196. Imai K, Natali PG, Kay NE, Wilson BS, Ferrone J. Tissue distribution and molecular profile of a differentiation antigen detected by a monoclonal antibody (345-1345) produced against human melanoma cells. Cancer Immunol Immunother 1982; 12:159-166.
197. Oken MM, Kay NE. T-cell subpopulations in multiple myeloma: correlation with clinical disease status. Br J Haematol 1981 Dec; 49(4):629-34.
     View PubMed
198. LeMarbre P, Rinehart JJ, Kay NE, Vesella R, Jacob HS. Lysozyme enhances monocyte-mediated tumoricidal activity: a potential amplifying mechanism of tumor killing. Blood 1981 Nov; 58(5):994-9.
     View PubMed
199. Allen JI, Kay NE, McClain CJ. Severe zinc deficiency in humans: association with a reversible T-lymphocyte dysfunction. Ann Intern Med 1981 Aug; 95(2):154-7.
     View PubMed
200. Ascensao JL, Kay NE, Banisadre M, Zanjani ED. Cell-cell interaction in human granulopoiesis: role of T lymphocytes. Exp Hematol 1981 May; 9(5):473-8.
     View PubMed
201. Ziegler HW, Kay NE, Zarling JM. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 1981 Mar 15; 27(3):321-7.
     View PubMed
202. Kay NE. Abnormal T-cell subpopulation function in CLL: excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation. Blood 1981 Mar; 57(3):418-20.
     View PubMed
203. Ascensao JL, Kay NE, Earenfight-Engler T, Koren HS, Zanjani ED. Production of erythroid potentiating factor(s) by a human monocytic cell line. Blood 1981 Jan; 57(1):170-3.
     View PubMed
204. Kay NE, Douglas SD. Detection of shedding of human blood monocyte Fc receptor during in vitro culture. International Archives of Allergy & Applied Immunology 1981; 66(2):131-5.
     View PubMed
205. Zuckerman SH, Kay NE, Douglas SD. Effect of adenosine deaminase inhibitors on Fc mu receptor expression in human T-cell cultures. Cell Immunol 1980 Nov; 56(1):112-9.
     View PubMed
206. Kay NE, Bumol TF, Douglas SD. Effects of 2-deoxy-D-glucose on human monocyte metabolism and function. J Reticuloendothel Soc 1980 Oct; 28(4):367-79.
     View PubMed
207. Kay NE, Ackerman SK, Douglas SD. Anatomy of the immune system. Semin Hematol 1979 Oct; 16(4):252-82.
     View PubMed
208. Kay NE, Douglas SD, Nelson RD. Human neutrophil migratory function: modulatory effect of interactions with opsonized particles. Infection & Immunity 1979 Oct; 26(1):12-4.
     View PubMed
209. Kay NE, Johnson JD, Stanek R, Douglas SD. T-cell subpopulations in chronic lymphocytic leukemia: abnormalities in distribtuion and in in vitro receptor maturation. Blood 1979 Aug; 54(2):540-4.
     View PubMed
210. Gordon LI, Douglas SD, Kay NE, Yamada O, Osserman EF, Jacob HS. Modulation of neutrophil function by lysozyme. Potential negative feedback system of inflammation. J Clin Invest 1979 Jul; 64(1):226-32.
     View PubMed
211. Kay NE, Douglas SD. Monocyte metabolic activation in patients with rheumatoid arthritis. Experimental Biology & Medicine 1979 Jul; 161(3):303-6.
     View PubMed
212. Kay NE, Ackerman SK, Douglas SD. Detachment of adherent human monocytes from glass surfaces induced by antibody-coated and uncoated erythrocytes. Clinical Immunology & Immunopathology 1979 Jul; 13(3):269-6.
     View PubMed
213. Harris RD, Kay NE, Seljeskog EL, Murray KJ, Douglas SD. Prolactin suppression of leukocyte chemotaxis in vitro. J Neurosurg 1979 Apr; 50(4):462-5.
     View PubMed
214. Smith JR, Kay NE, Gottlieb AJ, Oski FA. Abnormal erythrocyte metabolism in hepatic disease: effect of NADP repletion. Am J Hematol 1979; 6(4):313-21.
     View PubMed
215. Gordon LI, Hrushesky W, Oken MM, Kay NE, Rydell RE. Chronic lymphocytic leukemia in association with a second lymphoproliferative disorder: response to chemotherapy in two cases. Medical & Pediatric Oncology 1979; 7(2):111-6.
     View PubMed
216. Kay NE, Anderson K. Direct antiglobulin "Coombs'" test. Incidence of positive findings in normal population: retrospective study. N Y State J Med 1978 Jul; 78(8):1244-6.
     View PubMed
217. Ackerman SK, Bumol TF, Kay NE, Douglas SD. Cellular immunologic studies of a patient with monocytic leukemia. Am J Med 1978 Jun; 64(6):1061-8.
     View PubMed
218. Kay NE, Gordon LI, Douglas SD. Autoimmune hemolytic anemia in association with monoclonal IgM(kappa) with anti-i activity. Am J Med 1978 May; 64(5):845-50.
     View PubMed
219. Kay NE, Bumol TF, Douglas SD. Effect of phagocytosis and Fc receptor occupancy on complement-dependent neutrophil chemotaxis. Journal of Laboratory & Clinical Medicine 1978 May; 91(5):850-6.
     View PubMed
220. Murray KJ, Kay NE, Douglas SD. Blood-group antigens and antibodies in human brain-tumor cysts. J Neurosurg 1978 Feb; 48(2):164-8.
     View PubMed
221. Handwerger BS, Kay NE, Douglas SD. Lymphocyte-mediated antibody-dependent cytolysis: role in immune hemolysis. Vox Sang 1978; 34(5):276-80.
     View PubMed
222. Kay NE, Douglas SD. Monocyte-erythrocyte interaction in vitro in immune hemolytic anemias . Blood 1977 Nov; 50(5):889-97.
     View PubMed
223. Kay NE, Murray KJ, Douglas SD. Neutrophil chemotaxis in cerebral astrocytoma. Surg Neurol 1977 Oct; 8(4):255-7.
     View PubMed
224. Kay NE, Douglas SD. Mononuclear phagocyte. Development, structure, function, and involvement in immune response. N Y State J Med 1977 Mar; 77(3):327-39.
     View PubMed
225. Douglas SD, Kay NE. Fluctuations of lymphocyte surface markers in chronic lymphocytic leukemia. N Engl J Med 1976; 295:504-505.
226. Smith JR, Kay NE, Gottlieb AJ, Oski FA. Abnormal erythrocyte metabolism in hepatic disease. Blood 1975 Dec; 46(6):955-64.
     View PubMed
227. Kay NE, Douglas SD, Mond JJ, Flier JS, Kochwa S, Rosenfield RE. Hemolytic anemia with serum and erythrocyte-bound low-molecular-weight IgM. Clinical Immunology & Immunopathology 1975 Jul; 4(2):216-25.
     View PubMed
228. Kay NE, Douglas SD, Estren S. Letter: T-cells in chronic lymphocytic leukaemia. Lancet 1974 Nov 30; 2(7892):1326.
     View PubMed
229. Smith JR, Kay NE. Polycythemia-1973. Laboratory and clinical evaluation. Postgrad Med 1973 Dec; 54(6):141-4 passim.
     View PubMed
230. Kay NE, Gottlieb AJ. Hypouricemia in Hodgkin's disease. Report of an additional case. Cancer 1973 Dec; 32(6):1508-11.
     View PubMed
231. Kay NE, Stockman JA 3rd, Stuart MJ, Gottlieb AJ, Oski FA. Letter: Asparaginase-induced megaloblastic changes. JAMA 1973 Nov 5; 226(6):673.
     View PubMed
232. Kay NE, Nelson DA, Gottlieb AJ. Eosinophilic Pelger-Huet anomaly with myeloproliferative disorder. Am J Clin Pathol 1973 Nov; 60(5):663-8.
     View PubMed